After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Even though RGTI stock has already seen an impressive 1,300% increase over the past twelve months, the question persists: ...

Troubled REIT ARE shows massive upside potential with strong fundamentals and returns. Click for more on ARE stock and why it ...

The S&P 500 added 0.5% on Thursday, July 17, 2025, notching a record closing high for the first time in a week as June retail ...

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Moderna’s stock price has taken a beating over the past six months, shedding 33.6% of its value and falling to $26.85 per share. This was partly due to its softer quarterly results and may have ...